RGEN - 5 Numbers Repligen Investors Need to Know
Less than a decade ago, Repligen (NASDAQ: RGEN) was toiling away in clinical trials in an attempt to bring experimental drugs to market. Today, the company's former drug pipeline is a distant memory. It has instead gone all-in on bioprocess engineering products -- the filters, chromatography columns, sensors, and other tools needed to manufacture biologic drugs.
The niche has served the company and its shareholders well: Shares of Repligen have gained 2,430% in the last decade. But the growth opportunities are far from exhausted. To better understand where the company is headed, it helps to understand how the company arrived at its current state of operations. Here are some numbers that shine a light on its trajectory.
Image source: Getty Images.